Concentric Medical, which was recently acquired by Stryker, announced completion of enrolment of the TREVO (Thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke) study. The study assesses the ability of the Trevo system to remove the blood clots that cause strokes and to restore blood flow to the brain.
For the first time, this study will evaluate the Stentriever technology in a European, multicentre, prospective clinical trial. Positive interim data from the study were presented in May at the European Stroke congress by Olav Jansen, head of Neuroradiology at Universitatsklinikum Schleswig-Holstein Kiel, Germany and co-principal investigator or the study. The interim revascularisation rate in the first 36 patients was 96%. Thirty patients had 90-day follow up and 63% of these had a good outcome. A “good outcome” was defined as being functionally independent at 90 days (modified Rankin score of 2 or less).
“The TREVO study represents an important step forward in the evidence supporting the treatment of patients with moderate and severe strokes with mechanical thrombectomy devices, such as the Trevo system. The rigorous conduct of this prospective multicentre trial provides more confidence not only in patient selection, but in the successful procedural and clinical outcomes for these patients,” commented Nils Wahlgren, professor of Neurology at Karolinska University Hospital, Sweden, and co-principal investigator.
“The Trevo system is the first device of this type designed specifically for removal of the clot in ischaemic stroke patients. Not only was it easy to use, but the architectural properties of the device enhance clot integration into the device, making the procedures fast and remarkably effective,” commented Juan Macho, Hospital Clinic Barcelona, Spain.